Skip to main content
. 2001 Jan 30;98(4):1829–1834. doi: 10.1073/pnas.031582398

Figure 3.

Figure 3

Pituitary LH-RH-R mRNA expression and serum and pituitary LH in OVX rats during or after the treatment for 10 days with a depot formulation of Cetrorelix pamoate. (a) LH-RH-R mRNA level in normal rats, in OVX controls 11 and 21 days after ovariectomy, and in OVX rats treated with Cetrorelix for 10 days. (b) RT-PCR products of the pituitary LH-RH-R mRNA and β-actin mRNA, after separation by agarose gel electrophoresis and staining with ethidium bromide. Lane M, 100-bp DNA molecular weight marker; lanes 1, 2, and 3, Cetrorelix-treated; lanes 4, 5, and 6, untreated control. (c) Time course of serum LH measured on days 0, 1, 4, 7, and 10 of the Cetrorelix treatment. (d) Total pituitary LH content after the treatment (% untreated control). **, P < 0.01 vs. control; ++, P < 0.01 vs. pretreatment levels on day 0.